TD Cowen analyst Kyle Boucher maintained a Buy rating on Bio-Techne today and set a price target of $65.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyle Boucher has given his Buy rating due to a combination of factors that highlight a promising long-term outlook for Bio-Techne. Despite current macroeconomic pressures and challenges such as tariffs and NIH funding headwinds, Boucher believes these are already factored into the stock’s valuation and may be overstated. The feedback from investors, particularly long-only investors, has been positive, indicating a renewed interest in the stock.
Additionally, surveys conducted with pharma/biotech and academic customers reveal a favorable spending outlook on core reagents, suggesting a strong market position for Bio-Techne. While near-term challenges persist, the expectation of increased customer spending next year supports a positive long-term view. This combination of factors underpins Boucher’s confidence in the stock’s potential for growth, justifying the Buy rating.
In another report released on July 23, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $60.00 price target.